Biogen Pharmachem Industries L Overview
Get informed when a big investor buys or sells
+ Follow0.58%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Biogen Pharmachem Industries L (BIOGEN.BO) currently reports a ROE of 0.58%. That is below the sector sector average of 11.3%. Use the charts on this page to explore Biogen Pharmachem Industries L's ROE history and peer comparisons.
Biogen Pharmachem Industries L's ROE of 0.58% is lower than the its sector sector average of 11.3%. That is roughly 94.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Biogen Pharmachem Industries L's current 0.58% should be judged against industry norms (sector average: 11.3%) and against BIOGEN.BO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 0.58%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.3%. From there, open related valuation or income-statement pages for Biogen Pharmachem Industries L, and consider following BIOGEN.BO for alerts when major investors trade the stock.
